These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35274673)

  • 1. Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease.
    Keshavarz Shahbaz S; Mansourabadi AH; Jafari D
    Clin Exp Immunol; 2022 May; 208(1):12-24. PubMed ID: 35274673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
    Ringdén O; Moll G; Gustafsson B; Sadeghi B
    Front Immunol; 2022; 13():839844. PubMed ID: 35371003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.
    Markov A; Thangavelu L; Aravindhan S; Zekiy AO; Jarahian M; Chartrand MS; Pathak Y; Marofi F; Shamlou S; Hassanzadeh A
    Stem Cell Res Ther; 2021 Mar; 12(1):192. PubMed ID: 33736695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications.
    Huang Y; Wu Q; Tam PKH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.
    Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management.
    Mirfakhraie R; Ardakani MT; Hajifathali A; Karami S; Moshari MR; Hassani M; Firouz SM; Roshandel E
    Transpl Immunol; 2022 Apr; 71():101524. PubMed ID: 34990789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEACAM1-engineered MSCs have a broad spectrum of immunomodulatory functions and therapeutic potential via cell-to-cell interaction.
    Yi E; Go J; Yun SH; Lee SE; Kwak J; Kim SW; Kim HS
    Biomaterials; 2024 Dec; 311():122667. PubMed ID: 38878480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic applications of mesenchymal stromal cells.
    Larsen S; Lewis ID
    Pathology; 2011 Oct; 43(6):592-604. PubMed ID: 21876470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease.
    Tang B; Li X; Liu Y; Chen X; Li X; Chu Y; Zhu H; Liu W; Xu F; Zhou F; Zhang Y
    Cell Physiol Biochem; 2018; 46(6):2624-2635. PubMed ID: 29763906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?
    Introna M; Golay J
    Front Immunol; 2020; 11():609063. PubMed ID: 33362797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mesenchymal stem cells for treatment of graft-versus-host disease].
    Najima Y
    Rinsho Ketsueki; 2017; 58(12):2440-2449. PubMed ID: 29332881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breaking the graft-versus-host-disease barrier: Mesenchymal stromal/stem cells as precision healers.
    Mendiratta M; Mendiratta M; Mohanty S; Sahoo RK; Prakash H
    Int Rev Immunol; 2024; 43(2):95-112. PubMed ID: 37639700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
    Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
    Front Immunol; 2019; 10():619. PubMed ID: 31001253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease.
    Yang H; Cheong S; He Y; Lu F
    Stem Cell Res Ther; 2023 Dec; 14(1):372. PubMed ID: 38111001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive properties of mesenchymal stem cells: advances and applications.
    De Miguel MP; Fuentes-Julián S; Blázquez-Martínez A; Pascual CY; Aller MA; Arias J; Arnalich-Montiel F
    Curr Mol Med; 2012 Jun; 12(5):574-91. PubMed ID: 22515979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of Graft-versus-Host-Disease in NOD.Cg-Prkdc
    Hansen M; Stahl L; Heider A; Hilger N; Sack U; Kirschner A; Cross M; Fricke S
    Transplant Cell Ther; 2021 Aug; 27(8):658.e1-658.e10. PubMed ID: 33964513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human bone marrow mesenchymal stromal/stem cells: current clinical applications and potential for hematology.
    Miura Y
    Int J Hematol; 2016 Feb; 103(2):122-8. PubMed ID: 26692196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multipotent mesenchymal stromal cells application for acute graft versus host disease treatment].
    Kuzmina LA; Petinati NA; Vasilieva VA; Dovydenko MV; Drokov MY; Davydova YO; Kapranov NM; Sats NV; Chabaeva YA; Kulikov SM; Gaponova TV; Drize NI; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2020 Sep; 92(7):23-30. PubMed ID: 33346442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.